Skip to main content

Table 4 Baseline patient characteristics (patients grouped according to treatment order)

From: Safety and efficacy of long-term combination therapy with bezafibrate and ezetimibe in patients with dyslipidemia in the prospective, observational J-COMPATIBLE study

Characteristics EZE + BEZA BEZA + EZE BEZA & EZE
n mean ± SD/% n mean ± SD/% n mean ± SD/%
Age (years) 174 62.5 ± 12.9 257 59.2 ± 12.0 228 61.2 ± 14.2
Men (%) 94 54.0 173 67.3 117 51.3
With complications (%) 152 87.4 220 85.6 179 78.5
Concurrent disease       
 Hypertension (%) 106 60.9 141 54.9 121 53.1
 Diabetes (%) 61 35.1 100 38.9 69 30.3
 Hepatic disease (%) 34 19.5 68 26.5 50 21.9
 Cardiac disease (%) 8 4.6 19 7.4 19 8.3
 Renal disease (%) 2 1.1 8 3.1 10 4.4
Purpose of combination therapya       
 Primary prevention (%) 152 87.4 245 95.3 207 90.8
 Secondary prevention (%) 5 2.9 11 4.3 10 4.4
 Unknown (%) 17 9.8 1 0.4 11 4.8
Concomitant medications       
 Drugs for hypertension (%) 104 59.8 141 54.9 110 48.2
 Drugs for diabetes (%) 44 25.3 72 28.0 47 20.6
 Statin (%) 3 1.7 4 1.6 7 3.1
  1. Data are expressed as mean ± standard deviation or n and percent.
  2. aDefined according to the Guidelines for the Prevention of Atherosclerotic Cardiovascular Disease 2007 [9]. EZE + BEZA: patients who were already taking ezetimibe and then added bezafibrate at the start of the study; BEZA + EZE: patients who were already taking bezafibrate and then added ezetimibe at the start of the study; BEZA & EZE: patients who started bezafibrate and ezetimibe concurrently.